Navigation Links
Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

sing patients to lung infections, which continually damage their lungs. Pulmonary infection with Gram-negative bacteria, particularly pulmonary P. aeruginosa, represents the single greatest cause of morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including statements related to Gilead's ability to obtain data from AIR-CF1 and submit an NDA for aztreonam lysine for inhalation for the treatment of CF to the U.S. FDA as currently planned. For example, the safety and efficacy data from additional clinical studies may not warrant further development of this compound and initiating and completing clinical trials may take longer or cost more than expected. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, the U.S. FDA may not approve aztreonam lysine for inhalation for the treatment of CF in the United States, and any marketing approval, if granted, may have significant limitations on its use. These risks, uncertainties and other factors could cause actual results to differ materially fr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... report second quarter 2014 financial results before the NASDAQ ... That same day, Arena will host a conference call ... Pacific Time). The conference call may ... 914.495.8552 for international callers. Please specify to the operator ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... , CHICAGO , Jan. 14 ... Raman detection system for ultrasensitive immunoassays.  The system provides ... of low abundance markers.  These increases in performance could ... discovery, and clinical diagnostics development. , "We find the ...
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
Cached Medicine Technology:Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays. 2Custom Spine Announces the Expansion of its Sales Management Team 2
(Date:7/25/2014)... UT (PRWEB) July 25, 2014 ... surfaces for the recent Nike National Invitational Tournament ... current United States Junior National Tournament (USJN) ... 25. , The flooring for these prestigious national tournaments ... than 300,000 square feet of playing surface at McCormick ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Florida Hospital and ... two not-for-profit organizations for years to come and make a ... with a $2 million dollar check to provide the support ... investment will enable MOSI to transform the IMAX Dome Theatre ... MOSI has the only IMAX Dome Theatre in the state ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
(Date:7/25/2014)... July 25, 2014 This is ... state of the Galactooligosaccharides (GOS) industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3
... Document Management,(Tricom), a company specializing in the electronic ... clientele, has announced the acquisition of,Pacific Data Centers, ... services to its clients so that they can ... 1967, PDC utilizes the latest technological advances and,state-of-the-art ...
... U.S. Senate to vote soon on legislation that ... Mississippi, WASHINGTON, July 9 Seniors across,Mississippi ... Medicare,Advantage program in legislation being considered in the ... million from the Medicare Advantage,program in Mississippi alone ...
... McCain Wrong on Veterans Health Care, WASHINGTON, ... Government Employees (AFGE) launched a nationwide radio ad,campaign ... health care. In addition to the radio ads, ... Affairs, launched a Web site, http://www.fundtheva.com, and ...
... Rochester Medical Center (URMC) will collaborate with the U.S. ... repository of data that will aid academic and industry ... addition to helping researchers understand many cardiac problems, the ... detect drugs that can have dangerous effects on the ...
... DALLAS, July 9 The Maltese healthcare system,will ... leaders from around the,world learn how the island ... model for the European Union to follow. Affiliated,Computer ... discuss the future,of healthcare and information technology while ...
... behavior threaten safety, quality, OAKBROOK TERRACE, Ill., July ... can test the limits of,civility in the workplace. A ... rude language and hostile behavior among health care,professionals goes ... safety and the overall quality of care., Intimidating ...
Cached Medicine News:Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Union Representing VA Workers Launch Nationwide Radio Campaign, Web Site and Viral Videos for Full VA Funding 2Health News:URMC, FDA to collaborate on national data repository for heart research 2Health News:URMC, FDA to collaborate on national data repository for heart research 3Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 2Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 3
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Angled shafts with 11 mm long tips. Jaws have longitudinal meshing serrations. Slide lock and serrated handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Medicine Products: